2Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens, 1999, 17∶151-183.
3National Institutes of Health, National Heart, Lung, and Blood Institute. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med, 1997, 157∶2413-2446.[Erratum, Arch Int
4Karch F, Lasagna L. Adverse drug reactions: a critical review. JAMA,1975,234∶1236-1241.
5Lip GYH, Beevers DG. A survey of the current practice of treating hypertension in primary care: the rational evaluation and choice in hypertension (REACH) study. J Drug Devel Clin Pract, 1996, 8∶161-169.
6Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep, 2000,2∶515-524.
7Dusing R, Weisser B, Mengden T, et al. Changes in antihypertensive therapy-the role of adverse effects and compliance. Blood Press, 1998,7∶313-315.
8Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin Ⅱ receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther, 2001,23∶1999-2010.
9Benson S, Vance-Bryan K, Raddatz J. Time to patient discontinuation of antihypertensive drugs in difference classes. Am J Health Syst Pharm, 2000,57∶51-54.
10Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA, 1997,277∶739-745.
